Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Smruthi Vijayaraghavan"'
Autor:
Ricardo Rivera-Soto, Benjamin Henley, Marian A. Pulgar, Stacey L. Lehman, Himanshu Gupta, Kia Z. Perez-Vale, Megan Weindorfer, Smruthi Vijayaraghavan, Tsun-Wen Sheena Yao, Sylvie Laquerre, Sheri L. Moores
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Amivantamab is an FDA-approved bispecific antibody targeting EGF and Met receptors, with clinical activity against EGFR mutant non-small cell lung cancer (NSCLC). Amivantamab efficacy has been demonstrated to be linked to three mechanisms of
Externí odkaz:
https://doaj.org/article/dd29589b1b0e4788a2ded682757cbef6
Autor:
Smruthi Vijayaraghavan, Cansu Karakas, Iman Doostan, Xian Chen, Tuyen Bui, Min Yi, Akshara S. Raghavendra, Yang Zhao, Sami I. Bashour, Nuhad K. Ibrahim, Meghan Karuturi, Jing Wang, Jeffrey D. Winkler, Ravi K. Amaravadi, Kelly K. Hunt, Debu Tripathy, Khandan Keyomarsi
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-17 (2017)
CDK4/6-Cyclin D pathway is often deregulated in cancer; therefore specific inhibitors have been developed. Here the authors show that treatment with CDK4/6 inhibitors activate autophagy in breast cancer cells; thus, combination of such inhibitors wit
Externí odkaz:
https://doaj.org/article/29244e97db3b4325b02bb495622f99c7
Autor:
Byoung Chul, Cho, Allison, Simi, Joshua, Sabari, Smruthi, Vijayaraghavan, Sheri, Moores, Alexander, Spira
Publikováno v:
Clinical Lung Cancer. 24:89-97
Substantial therapeutic advancements have been made in identifying and treating activating mutations in advanced non-small cell lung cancer (NSCLC); however, resistance to epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition
Autor:
Khandan Keyomarsi, Kelly K. Hunt, Mark J. McArthur, Smruthi Vijayaraghavan, Dong Yang, Yufeng Jiang, Tuyen Bui, Xian Chen, Natalie A. Jabbour-Leung
Two supplemental Tables are included in this file. The title of the supplemental tables are: Supplemental Table 1A. Hormone receptor, Her2, p53 and Rb status of breast cell lines examined . Supplemental Table 1B. Cell number and drug concentrations u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17ef08f622c4a6b08c48eaea0182c86d
https://doi.org/10.1158/1535-7163.22508805
https://doi.org/10.1158/1535-7163.22508805
Autor:
Sheri L. Moores, Sylvie Laquerre, Matthew V. Lorenzi, Kathryn Packman, Hillary J. Millar, Marilda Beqiri, Jocelyn Sendecki, Ryan Lenhart, Benjamin Henley, Barbara S. Bushey, Kristen Chevalier, Lorraine Lipfert, Smruthi Vijayaraghavan
Live cell imaging of M2 macrophage mediated trogocytosis in adherent co-culture
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cf87af4285c3d0237f323a012dd937b
https://doi.org/10.1158/1535-7163.22518970.v1
https://doi.org/10.1158/1535-7163.22518970.v1
Autor:
Khandan Keyomarsi, Lauren Averett Byers, Jing Wang, Kelly K. Hunt, John V. Heymach, Steve Warner, Tuyen N. Bui, Jason P.W. Carey, Youhong Fan, Pan Tong, Lixia Diao, Smruthi Vijayaraghavan, Kavitha Balaji
Supplementary Fig. 1. AXL is a direct mediator of EMT Supplementary Fig. 2. AXL inhibition causes DNA damage and reduces levels of DNA repair markers. Supplementary Fig. 3. AXL knockdown cause DNA damage and decreases gene expression of DNA repair ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a0757490212a25b465827ce70bedfee
https://doi.org/10.1158/1541-7786.22517842
https://doi.org/10.1158/1541-7786.22517842
Autor:
Kelly K. Hunt, Khandan Keyomarsi, Vinod Ravi, Neeta Somaiah, Tuyen Bui, Dong Yang, Kwang Hui Low, Smruthi Vijayaraghavan, Yanna Liu, Angela Alexander, Ashleigh M. Francis
Supplemental Table 1 - Cell line culture conditions and HTSA plating density Supplemental Table 2 - Concentrations of drugs used in HTSA assays Supplemental Table 3 - PDX information
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::242b0aea8571bddaffbe62c6a5684825
https://doi.org/10.1158/1535-7163.22508460
https://doi.org/10.1158/1535-7163.22508460
Autor:
Sheri L. Moores, Sylvie Laquerre, Matthew V. Lorenzi, Kathryn Packman, Hillary J. Millar, Marilda Beqiri, Jocelyn Sendecki, Ryan Lenhart, Benjamin Henley, Barbara S. Bushey, Kristen Chevalier, Lorraine Lipfert, Smruthi Vijayaraghavan
Contains Supplementary methods, supp figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8938da80853fda873f747b0495ab89f0
https://doi.org/10.1158/1535-7163.22518967
https://doi.org/10.1158/1535-7163.22518967
Autor:
Kelly K. Hunt, Khandan Keyomarsi, Vinod Ravi, Neeta Somaiah, Tuyen Bui, Dong Yang, Kwang Hui Low, Smruthi Vijayaraghavan, Yanna Liu, Angela Alexander, Ashleigh M. Francis
Supplemental Figure 1: Schematic of HTSA and dose response curves of doxorubicin and AZD-1775 in different cell lines. Supplemental Figure 2: Cell cycle analysis following palbociclib treatment. Supplemental Figure 3: Schematic of combination index d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d1003ef86e4896d1ae48c52bdbcd00a
https://doi.org/10.1158/1535-7163.22508457.v1
https://doi.org/10.1158/1535-7163.22508457.v1
Autor:
Sheri L. Moores, Sylvie Laquerre, Matthew V. Lorenzi, Kathryn Packman, Hillary J. Millar, Marilda Beqiri, Jocelyn Sendecki, Ryan Lenhart, Benjamin Henley, Barbara S. Bushey, Kristen Chevalier, Lorraine Lipfert, Smruthi Vijayaraghavan
Small molecule inhibitors targeting mutant EGFR are standard of care in non–small cell lung cancer (NSCLC), but acquired resistance invariably develops through mutations in EGFR or through activation of compensatory pathways such as cMet. Amivantam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bfc5a7fffe067a0b3eccd7a83c5d4b
https://doi.org/10.1158/1535-7163.c.6542206.v1
https://doi.org/10.1158/1535-7163.c.6542206.v1